News & Updates

Show Multimedia Only

Cancer history does not factor in COVID-19, related outcomes among older women

24 Aug 2025

A history of cancer in older women appears to have no negative impact on the risks of COVID-19 and its outcomes, as reported in a study.

Cancer history does not factor in COVID-19, related outcomes among older women

24 Aug 2025

Lung nodule surveillance programme helps detect early-stage lung cancer

22 Aug 2025 by

A lung nodule surveillance programme at Queen Mary Hospital (QMH) facilitates diagnosis of early-stage lung cancer. Data from the programme’s first year of implementation showed a higher proportion of early-stage lung cancer diagnoses compared with the Hong Kong Cancer Registry’s (HKCR) annual report.

Lung nodule surveillance programme helps detect early-stage lung cancer

22 Aug 2025

Sintilimab plus axitinib shows therapeutic potential in FH-deficient RCC

19 Aug 2025

The combination of sintilimab plus axitinib demonstrates encouraging antitumour activity in patients with fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) while having a manageable safety profile, according to a phase II study conducted in China.

Sintilimab plus axitinib shows therapeutic potential in FH-deficient RCC

19 Aug 2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

19 Aug 2025

New drug applications approved by US FDA as of 1-15 July 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

19 Aug 2025

Radiotherapy plus sacituzumab govitecan feasible in metastatic breast cancer

14 Aug 2025

Concurrent administration of sacituzumab govitecan and radiotherapy is well tolerated and does not lead to increased toxicity in patients with metastatic breast cancer, a study has shown.

Radiotherapy plus sacituzumab govitecan feasible in metastatic breast cancer

14 Aug 2025

Study supports early antibiotic suspension in kids with cancer, febrile neutropenia

14 Aug 2025 by

The E-STOP trial presented at ESHRE 2025 supports early antibiotic suspension in paediatric patients with cancer and febrile neutropenia (FN).

Study supports early antibiotic suspension in kids with cancer, febrile neutropenia

14 Aug 2025

Peg-filgrastim reduces neutropenia in children with solid tumours

13 Aug 2025

The incidence of febrile neutropenia (FN) is significantly lesser in children with solid tumours receiving pegylated filgrastim as primary prophylaxis following chemotherapy than in those assigned to filgrastim alone, reports a study. Moreover, no adverse events attributed to the study drug have been observed.

Peg-filgrastim reduces neutropenia in children with solid tumours

13 Aug 2025

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

13 Aug 2025

The growing range of treatment options for EGFR-mutated non-small cell lung cancer (NSCLC) has made first-line decisions more complex and more critical. Patients are increasingly more aware of new and different treatment options and are seeking therapies that align with their personal values. As survival outcomes continue to improve, shared decision-making (SDM) plays a vital role in individualising care by integrating clinical evidence with what matters most to each individual. This article explores how SDM can support patient-centred care, drawing on insights from Professor James Yang and patient advocate Mark Brooke.

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

13 Aug 2025

Vorasidenib prevents seizures in mIDH1/2 gliomas

12 Aug 2025 by

Patients with grade 2 isocitrate dehydrogenase 1 or 2 mutant (mIDH1/2) gliomas receiving vorasidenib experience fewer seizure activities than those on placebo, as shown by the results of the INDIGO study.

Vorasidenib prevents seizures in mIDH1/2 gliomas

12 Aug 2025

Adiposity levels may predict CRC risk

11 Aug 2025

High adiposity levels are associated with the risk of colorectal cancer (CRC), suggest the results of a systematic review. However, standardization is necessary to improve understanding of the link between CRC and adiposity to enable comparisons across papers.

Adiposity levels may predict CRC risk

11 Aug 2025

News & Updates

Showing Oncology articles

Showing

Specialty:

Cancer history does not factor in COVID-19, related outcomes among older women

Cancer history does not factor in COVID-19, related outcomes among older women

Lung nodule surveillance programme helps detect early-stage lung cancer

Lung nodule surveillance programme helps detect early-stage lung cancer

Sintilimab plus axitinib shows therapeutic potential in FH-deficient RCC

Sintilimab plus axitinib shows therapeutic potential in FH-deficient RCC

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

Radiotherapy plus sacituzumab govitecan feasible in metastatic breast cancer

Radiotherapy plus sacituzumab govitecan feasible in metastatic breast cancer

Study supports early antibiotic suspension in kids with cancer, febrile neutropenia

Study supports early antibiotic suspension in kids with cancer, febrile neutropenia

Peg-filgrastim reduces neutropenia in children with solid tumours

Peg-filgrastim reduces neutropenia in children with solid tumours

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

Vorasidenib prevents seizures in mIDH1/2 gliomas

Vorasidenib prevents seizures in mIDH1/2 gliomas

Adiposity levels may predict CRC risk

Adiposity levels may predict CRC risk